CEL Competitors
| CVM Stock | USD 5.80 0.07 1.19% |
CEL SCI vs PDS Biotechnology Correlation
Significant diversification
The correlation between CEL SCI Corp and PDSB is 0.01 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CEL SCI Corp and PDSB in the same portfolio, assuming nothing else is changed.
Moving together with CEL Stock
Moving against CEL Stock
| 0.8 | KOD | Kodiak Sciences | PairCorr |
| 0.77 | VYNE | Vyne Therapeutics | PairCorr |
| 0.71 | FBIO | Fortress Biotech | PairCorr |
| 0.6 | KPTI | Karyopharm Therapeutics | PairCorr |
| 0.58 | VRTX | Vertex Pharmaceuticals Earnings Call Tomorrow | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CEL SCI's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CEL SCI Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CEL SCI and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CEL and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CEL SCI Corp does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CEL Stock performing well and CEL SCI Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CEL SCI's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INMB | 3.63 | (0.19) | 0.00 | (0.08) | 0.00 | 6.82 | 22.66 | |||
| BRNS | 3.10 | (0.71) | 0.00 | 0.89 | 0.00 | 5.71 | 24.01 | |||
| MRSN | 7.16 | 3.13 | 0.83 | 0.44 | 2.27 | 7.25 | 210.61 | |||
| ALGS | 4.53 | (0.14) | 0.00 | (1.15) | 0.00 | 10.16 | 28.43 | |||
| KZR | 0.74 | (0.04) | 0.00 | (0.44) | 0.00 | 1.46 | 7.79 | |||
| OKUR | 3.87 | (0.35) | 0.00 | 6.95 | 0.00 | 6.64 | 23.27 | |||
| TPST | 4.76 | (1.80) | 0.00 | (3.38) | 0.00 | 7.92 | 57.69 | |||
| XFOR | 3.23 | 0.09 | 0.03 | 0.10 | 3.90 | 7.57 | 23.09 | |||
| FGEN | 2.66 | (0.15) | 0.00 | 0.18 | 0.00 | 4.33 | 28.75 | |||
| PDSB | 4.07 | (0.14) | 0.00 | (0.02) | 0.00 | 8.60 | 27.78 |
Cross Equities Net Income Analysis
Compare CEL SCI Corp and related stocks such as INmune Bio, Barinthus Biotherapeutics, and Mersana Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| MRSN | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (13.7 M) | (38.7 M) | (64.3 M) | (28.2 M) | (88 M) | (170.1 M) | (204.2 M) | (171.7 M) | (69.2 M) | (62.3 M) | (65.4 M) |
| ALGS | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (52.3 M) | (108.5 M) | (128.3 M) | (96 M) | (87.7 M) | (131.2 M) | (118.1 M) | (124 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| TPST | (2.7 M) | (2.7 M) | (13.5 M) | (29 M) | (49.5 M) | (73.2 M) | (82.3 M) | (84.6 M) | (27.2 M) | (44.6 M) | (19.1 M) | (28.3 M) | (35.7 M) | (29.5 M) | (41.8 M) | (37.7 M) | (39.5 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (37.5 M) | (33.7 M) | (35.4 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
CEL SCI Corp and related stocks such as INmune Bio, Barinthus Biotherapeutics, and Mersana Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in CEL SCI Corp financial statement analysis. It represents the amount of money remaining after all of CEL SCI Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.CEL SCI Competitive Analysis
The better you understand CEL SCI competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CEL SCI's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CEL SCI's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
CEL SCI Competition Performance Charts
Five steps to successful analysis of CEL SCI Competition
CEL SCI's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by CEL SCI Corp in relation to its competition. CEL SCI's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of CEL SCI in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CEL SCI's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to CEL SCI Corp, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your CEL SCI position
In addition to having CEL SCI in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CEL SCI Correlation with its peers. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could CEL diversify its offerings? Factors like these will boost the valuation of CEL SCI. Projected growth potential of CEL fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CEL SCI data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.27) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
Understanding CEL SCI Corp requires distinguishing between market price and book value, where the latter reflects CEL's accounting equity. The concept of intrinsic value—what CEL SCI's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CEL SCI's price substantially above or below its fundamental value.
It's important to distinguish between CEL SCI's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CEL SCI should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CEL SCI's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.